(Alliance News) - Syncona Ltd on Monday said portfolio company Freeline Therapeutics Holdings PLC has filed a registration statement with the US Securities & Exchange Commission for a proposed initial public offering in the US.
The London-based healthcare investor said Freeline has applied to list ADSs on the Nasdaq Global Select Market. Freeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver.
The number and price of Freeline's American depositary shares are yet to be determined. The offering will also be subject to market conditions meaning there is no assurance as to when the offering will be completed, Syncona said.
Although the registration has been filed with the US SEC, it has not yet come into effect.
Syncona's shares were up 0.2% at 254.50 each early on Monday morning in London.
By Greg Roxburgh; gregroxburgh@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.